Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? / Christensen, Mikkel; Knop, Filip Krag.

In: Current Diabetes Reports, Vol. 10, No. 2, 01.04.2010, p. 124-32.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Christensen, M & Knop, FK 2010, 'Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?', Current Diabetes Reports, vol. 10, no. 2, pp. 124-32. https://doi.org/10.1007/s11892-010-0102-x

APA

Christensen, M., & Knop, F. K. (2010). Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Current Diabetes Reports, 10(2), 124-32. https://doi.org/10.1007/s11892-010-0102-x

Vancouver

Christensen M, Knop FK. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Current Diabetes Reports. 2010 Apr 1;10(2):124-32. https://doi.org/10.1007/s11892-010-0102-x

Author

Christensen, Mikkel ; Knop, Filip Krag. / Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?. In: Current Diabetes Reports. 2010 ; Vol. 10, No. 2. pp. 124-32.

Bibtex

@article{440f8fd3d3f4453492d02eb24f4bb756,
title = "Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?",
abstract = "Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.",
author = "Mikkel Christensen and Knop, {Filip Krag}",
year = "2010",
month = apr,
day = "1",
doi = "http://dx.doi.org/10.1007/s11892-010-0102-x",
language = "English",
volume = "10",
pages = "124--32",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Springer Healthcare",
number = "2",

}

RIS

TY - JOUR

T1 - Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

AU - Christensen, Mikkel

AU - Knop, Filip Krag

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.

AB - Incretin mimetics offer a new modality in diabetes treatment. This modality is based on the effects of the naturally occurring glucoregulatory gut hormone glucagon-like peptide-1 (GLP-1), which counteracts several pathophysiologic traits in type 2 diabetes. GLP-1 receptor agonists with extended half-lives entailing fewer injections and presumably an improved throughout-the-day glycemic control are in clinical development. This article summarizes the physiologic effects of GLP-1; the effects of the already marketed GLP-1 analogues for daily dosing, exenatide and liraglutide; and reviews the presently published data (with emphasis on clinical pharmacokinetics, efficacy, and safety) on GLP-1 agonists, which currently are in development and intended for once-weekly dosing: albiglutide/albugon, CJC-1131, CJC-1134-PC, exenatide once weekly, and taspoglutide.

U2 - http://dx.doi.org/10.1007/s11892-010-0102-x

DO - http://dx.doi.org/10.1007/s11892-010-0102-x

M3 - Journal article

VL - 10

SP - 124

EP - 132

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 2

ER -

ID: 34145035